Dengue vaccines: progress and challenges (Q37868122)

24 August 2017

1 reference

title

Dengue vaccines: progress and challenges (English)

1 reference

24 August 2017

0 references

Beth-Ann G. Coller

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21514129

30 November 2024

David E. Clements

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21514129

30 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21514129

30 November 2024

publication date

21 April 2011

1 reference

full work available at URL

24 August 2017

https://api.elsevier.com/content/article/PII:S0952791511000306?httpAccept=text/xml

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

https://api.elsevier.com/content/article/PII:S0952791511000306?httpAccept=text/plain

30 November 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Current Opinion in Immunology

30 November 2024

published in

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

391-398

1 reference

Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever

24 August 2017

cites work

1 reference

21 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NM887

Dengue: a continuing global threat

1 reference

21 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NRMICRO2460

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

The growing burden of dengue in Latin America

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Cost of dengue cases in eight countries in the Americas and Asia: a prospective study.

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels.

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Dengue and hemorrhagic fever: a potential threat to public health in the United States

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Update on the global spread of dengue

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

The global emergence/resurgence of arboviral diseases as public health problems

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Dengue in Southeast Asia: epidemiological characteristics and strategic challenges in disease prevention

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

The Epidemiology of Dengue in the Americas Over the Last Three Decades: A Worrisome Reality

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Serotype-Specific Differences in the Risk of Dengue Hemorrhagic Fever: An Analysis of Data Collected in Bangkok, Thailand from 1994 to 2006

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Immunological serotype interactions and their effect on the epidemiological pattern of dengue

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Emergence of the Asian 1 genotype of dengue virus serotype 2 in viet nam: in vivo fitness advantage and lineage replacement in South-East Asia

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Changing patterns of dengue epidemiology and implications for clinical management and vaccines

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

The impact of the demographic transition on dengue in Thailand: insights from a statistical analysis and mathematical modeling

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Dengue in the Americas and Southeast Asia: do they differ?

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Antibodies determine virulence in dengue

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

T lymphocyte responses to heterologous secondary dengue virus infections

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Understanding the contribution of cellular immunity to dengue disease pathogenesis

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

A re-evaluation of the mechanisms leading to dengue hemorrhagic fever

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Dengue immune response: low affinity, high febrility

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Genotype-specific neutralization and protection by antibodies against dengue virus type 3.

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Cross-reacting antibodies enhance dengue virus infection in humans

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Functional importance of dengue virus maturation: infectious properties of immature virions

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Immature Dengue Virus: A Veiled Pathogen?

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3).

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Development of Sanofi Pasteur tetravalent dengue vaccine

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Immunogenicity of sanofi pasteur tetravalent dengue vaccine

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Recent progress on sanofi pasteur's dengue vaccine candidate

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Development of a live attenuated dengue virus vaccine using reverse genetics

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult Volunteers

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COI.2011.03.005

30 November 2024

Identifiers

DOI

1 reference

24 August 2017

1 reference